Blood glucose regulatory enzyme

Blood glucose regulatory enzymes are a heterogeneous group of catalytic proteins that play pivotal roles in the digestion, absorption, and metabolic processing of carbohydrates to maintain systemic glucose homeostasis [1]. This group includes intestinal enzymes like alpha-glucosidase, which hydrolyzes oligosaccharides into absorbable monosaccharides [1], and systemic enzymes like dipeptidyl peptidase-4 (DPP-4), which regulates the half-life of insulinotropic incretin hormones [2]. Additionally, intracellular enzymes such as glucokinase act as metabolic sensors in the pancreas and liver [3], while others like glucose-6-phosphatase control the release of glucose from hepatic stores via gluconeogenesis and glycogenolysis [4]. In metabolic disorders like Type 2 Diabetes Mellitus, the activity of these enzymes is often dysregulated, contributing to persistent hyperglycemia and its associated complications [2]. Therapeutic strategies frequently involve the inhibition of these enzymes—such as using acarbose to delay glucose absorption or sitagliptin to enhance incretin activity—to restore glycemic balance and reduce hemoglobin A1c levels [1][2].

Other names

Glycemic regulatory enzymesEnzymes of glucose metabolismCarbohydrate metabolism enzymes

Drugs targeting these enzymes work through several distinct mechanisms: alpha-glucosidase inhibitors competitively inhibit intestinal enzymes to delay carbohydrate absorption [1]; DPP-4 inhibitors prevent the degradation of GLP-1 and GIP to enhance insulin secretion [2]; and glucokinase activators increase the sensitivity of the pancreatic glucose sensor to lower the threshold for insulin release [3].